May 4 - Amgen said on Monday it will invest an additional $300 million in Puerto Rico to grow its U.S. manufacturing presence. The company said the funding will be used to expand its biologics production facility in Juncos, Puerto Rico, a site that supplies medicines to more than 60 countries.
This $300 million commitment adds to previously announced investments in Puerto Rico. Last year Amgen disclosed $650 million in planned Puerto Rico investments, which the company said were expected to support the creation of 750 jobs.
The announcement arrives against the backdrop of recent U.S. policy action. In April, an executive order was signed imposing 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers either agreed to government drug-pricing deals or committed to producing their products domestically. The potential for such tariffs has prompted a number of global drugmakers to strengthen U.S.-based manufacturing.
Over the past year Amgen has outlined multiple large-scale investments across the United States. Those include a planned $900 million investment in Ohio and a $600 million allocation for a science and innovation center in California. The company has also reported investing more than $1.5 billion in North Carolina.
Amgen described the additional Puerto Rico funding as part of its broader effort to expand manufacturing capacity within the United States and its territories. The Juncos facility was highlighted for its role in distributing biologic medicines internationally, serving customers in excess of 60 countries.
Context and implications
- The additional $300 million commitment bolsters Amgen's manufacturing footprint in Puerto Rico and complements previous U.S. investments.
- The move is presented in the context of potential U.S. tariffs on imported branded medicines, which could be applied unless manufacturers meet specified pricing or domestic production conditions.
- Amgen's recent capital allocations include significant projects in Ohio, California and North Carolina, underlining a multi-state manufacturing and innovation strategy.
The company framed the expansion as an effort to increase domestic production capacity and support global distribution from its Juncos biologics site. Beyond the capital figures and stated job expectations, the announcement did not provide additional operational timelines or further detail on specific manufacturing lines to be expanded.